natgillin/translations-raw huggingface dataset:
The relative proportion of the two enantiomers remained constant over the dose range studied and there was no evidence of relative accumulation of one enantiomer over the other after repeated dosing.
Relativni delež dveh enantiomer je ostal konstanten v preučevanem razponu odmerka; znakov relativne akumulacije ene od enantiomer na račun druge po večkratnem odmerjanju niso opazili.
The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare
(≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki
Absorption of formoterol is linear following inhalation of 12 to 96 micrograms of formoterol.
Absorpcija formoterola je linearna po inhalaciji 12 do 96 mikrogramov formoterola.
If this occurs you should stop using Riarify and use your quick-acting “reliever” inhaler straightaway to treat the shortness of breath and wheezing.
Če se to zgodi, prenehajte uporabljati zdravilo Riarify in nemudoma uporabite hitrodelujoči "inhalator z olajševalcem", da boste obvladali kratko sapo in piskajoče dihanje.
• some anaesthetics can increase the risk of abnormal heart rhythms.
• nekaterimi anestetiki lahko poveča tveganje za nepravilnosti srčnega ritma;
Riarify can reduce exacerbations (flare-ups) of COPD symptoms.
Zdravilo Riarify lahko zmanjša poslabšanja (izbruhe) simptomov KOPB.
Pressurised container (coated aluminium), with a metering valve.
Tlačni vsebnik (obložen z aluminijem) z odmernim ventilom.
When to get a new inhaler
Kdaj morate dobiti nov inhalator
Riarify should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Uporabo zdravila Riarify je treba takoj prekiniti, bolnika pregledati in uvesti drugo zdravljenje, če je to potrebno.
The maximum dose is two inhalations of Riarify twice daily.
Največji odmerek sta dve inhalaciji zdravila Riarify dvakrat na dan.
injection while after inhalation in COPD patients it ranged from 5 to 12 hours at steady state.
injiciranju, medtem ko je bil po inhalaciji pri bolnikih s KOPB v razponu od 5 do 12 ur v stanju dinamičnega ravnovesja.
Infants and neonates born to mothers receiving substantial doses of Riarify should be observed for adrenal suppression.
Pri dojenčkih in novorojenčkih, rojenim materam, ki so prejele večje odmerke zdravila Riarify, je treba zato spremljati pojav zaviranja nadledvičnih žlez.
Riarify is a medicine to help breathing that contains the three active substances:
Zdravilo Riarify pomaga pri dihanju in vsebuje tri učinkovine:
Repeat dose toxicity
Toksičnost pri ponavljajočih odmerkih
Riarify should only be used during pregnancy if the expected benefit to the patient outweighs the potential risk to the foetus.
Zdravilo Riarify se lahko med nosečnostjo uporablja le, če so pričakovane koristi za mater večje od možnega tveganja za zarodek.
Their action is mediated by the binding to glucocorticoid receptors in the cytoplasm resulting in the increased transcription of genes coding for antiinflammatory proteins.
Njihovo delovanje poteka z vezavo glukokortikoidnih receptorjev v citoplazmi, kar poveča transkripcijo genov, ki kodirajo protivnetne proteine.
What Riarify is and what it is used for
Kaj je zdravilo Riarify in za kaj ga uporabljamo
Patients should then check the dose counter or dose indicator to ensure it has moved accordingly.
Bolnik naj nato preveri števec odmerka ali kazalnik odmerka in se prepriča, da se je števec ustrezno premaknil.
Other medicines and Riarify
Druga zdravila in zdravilo Riarify
Chemical and physical in-use stability has been demonstrated for 4 months at 25°C.
Kemična in fizikalna stabilnost za uporabo sta bili dokazani za 4 mesece pri temperaturi 25 °C.
Carcinogenicity studies have not been performed with Riarify.
Študij kancerogenosti za zdravilo Riarify niso izvedli.
Breathe out as slowly and deeply as possible, in order to empty your lungs.
Čim počasneje in čim bolj globoko izdihnite, kolikor je le mogoče, da izpraznite pljuča.
It is reasonable to assume that beclometasone dipropionate and its metabolites are also excreted into breast-milk.
Razumno je predvidevati, da se tudi beklometazondipropionat in njegovi presnovki izločajo v materino mleko.
Peak plasma concentrations of the unchanged active substance occur within 0.5 to 1 hours after oral administration.
Največje koncentracije nespremenjene učinkovine v plazmi se pojavijo v 0,5 do 1 ure po peroralni uporabi.
Patients should not breathe out into the inhaler.
Bolnik ne sme izdihniti v inhalator.
The use of Riarify with the AeroChamber Plus spacer in COPD patients increased the lung delivery of beclometasone 17-monopropionate, formoterol and glycopyrronium (maximum plasma concentration increased by 15%, 58% and 60% respectively).
Učinek nastavka Uporaba zdravila Riarify z nastavkom AeroChamber Plus pri bolnikih s KOPB je povečala v pljučih doseženo količino beklometazon 17-monopropionata, formoterola in glikopironija (največja koncentracija v plazmi se je povečala za 15 %, 58 % oz. 60 %).
They may also increase the risk of disturbances of heart rhythm (ventricular arrhythmias).
Poveča se lahko tudi tveganje za motnje srčnega ritma (prekatne aritmije);
Vision, blurred1 (see also section 4.4)
Očesne bolezni zamegljen vid1 (glejte tudi poglavje 4.4)
The absolute bioavailability following inhalation is approximately 2% and 62% of the nominal dose for unchanged beclometasone dipropionate and beclometasone 17-monopropionate respectively.
Absolutna biološka uporabnost po inhalaciji je približno 2 % nominalnega odmerka za nespremenjen beklometazondipropionat in 62 % za beklometazon 17-monopropionat.
To ensure proper administration of the medicinal product, the patient should be shown how to use the inhaler correctly by a physician or other healthcare professional, who should also regularly check the adequacy of the patient's inhalation technique.
Za zagotovitev pravilne uporabe zdravila mora zdravnik ali drug zdravstveni delavec bolniku pokazati, kako se inhalator pravilno uporablja, nato pa redno preverjati ustreznost bolnikove tehnike inhaliranja.
For the regular cleaning of the inhaler, patients should remove weekly the cap from the mouthpiece and wipe the outside and inside of the mouthpiece with a dry cloth.
Za redno čiščenje inhalatorja mora bolnik vsak teden sneti pokrov z ustnika in ustnik od zunaj in znotraj obrisati s suho krpo.
60 actuation pressurised container: 21 months.
Tlačni vsebnik s 60 sprožitvami: 21 mesecev.
Stand or sit up when inhaling.
Med vdihavanjem stojte ali sedite.
In order to reduce the risk of oropharyngeal candida infection, patients should be advised to rinse their mouth or gargle with water without swallowing it or brush their teeth after inhaling the prescribed dose.
Z namenom zmanjšanja orofaringealnih okužb s kandido je treba bolnikom svetovati, da si usta izperejo z vodo ali jo grgrajo, a naj je ne pogoltnejo, ali da si po inhaliranju predpisanega odmerka umijejo zobe.
If you are using Riarify or high doses of other inhaled corticosteroids over long periods and you come into a situation of stress (e.g. being taken to hospital after an accident, having a serious injury or before an operation) you may need more of this medicine.
Če uporabljate zdravilo Riarify ali velike odmerke inhaliranih kortikosteroidov in ste v stresni okoliščini (npr. če vas po nesreči odpeljejo v bolnišnico, če imate resno poškodbo ali pred operacijo)
The metabolic pattern of glycopyrronium in vitro (humans, dogs, rats, mice and rabbits liver microsomes and hepatocytes) was similar among species and the main metabolic reaction was the hydroxylation on the phenyl or ciclopentyl rings.
Presnovni vzorec glikopironija in vitro (jetrni mikrosomi in hepatociti ljudi, psov, podgan, miši in kuncev) je bil med vrstami podoben, pri čemer je bila glavna presnovna reakcija hidroksilacija na fenilnih ali ciklopentilnih obročih.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Riarify therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mothers.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Riarify, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
If signs suggesting allergic reactions occur, in particular, angioedema (including difficulties in breathing or swallowing, swelling of the tongue, lips and face), urticaria or skin rash, Riarify should be discontinued immediately and alternative therapy instituted.
ki kažejo na alergijsko reakcijo, zlasti angioedem (vključno s težavami pri dihanju ali požiranju, oteklostjo jezika, ustnic in obraza), urtikarijo ali kožni izpuščaj, je treba uporabo zdravila Riarify takoj prekiniti in uvesti drugo zdravljenje.
An overdose of Riarify may produce signs and symptoms due to the individual component's actions, including those seen with overdose of other beta2-agonists or anticholinergics and consistent with the known inhaled corticosteroid class effects (see section 4.4).
Preveliko odmerjanje zdravila Riarify lahko povzroči znake in simptome zaradi delovanja posamičnih sestavin, vključno s tistimi, ki se pojavijo pri prevelikem odmerjanju drugih agonistov adrenergičnih receptorjev beta2 ali antiholinergikov in so skladni z znanimi učinki razreda inhalacijskih kortikosteroidov (glejte poglavje 4.4).
After oral administration (40 to 80 micrograms), 6% to 10% of the dose was recovered in urine as unchanged active substance in healthy subjects; up to 8% of the dose was recovered as the glucuronide.
Po peroralnem dajanju (40 do 80 mikrogramov) so pri zdravih prostovoljcih 6 % do 10 % odmerka potrdili v urinu v obliki nespremenjene učinkovine; do 8 % odmerka so potrdili v obliki glukuronida.
They should be advised by their doctor or pharmacist about the proper use and care of their inhaler and spacer and their technique checked to ensure optimum delivery of the inhaled active substance to the lungs.
Zdravnik ali farmacevt mora bolnikom svetovati o pravilni uporabi in negi inhalatorja in nastavka ter o tehniki preverjanja zagotovitve optimalne dostavitve inhalirane učinkovine v pljuča.
However, an increase in total systemic exposure of up to 2.5-fold was observed in subjects with severe renal impairment (glomerular filtration rate below 30 mL/min/1.73 m2), as a consequence of a significant reduction of the amount excreted in urine (approximately 90% reduction of glycopyrronium renal clearance).
Vendar pa so opazili povečanje skupne sistemske izpostavljenosti za do 2,5-krat pri osebah s hudo okvaro ledvic (stopnja glomerularne filtracije pod 30 ml/min/1,73 m2) kot posledica močnega zmanjšanja količine, izločene v urin (približno 90-odstotno zmanjšanje ledvičnega očistka glikopironija).
Riarify can be used at the recommended dose in patients with mild to moderate renal impairment.
Zdravilo Riarify se lahko uporablja v priporočenem odmerku pri bolnikih z blago do zmerno okvaro ledvic.
This should be treated immediately with a fast-acting inhaled bronchodilator (reliever).
To je treba takoj zdraviti s hitrodelujočim inhalacijskim bronhodilatatorjem
The bioavailability of swallowed beclometasone dipropionate is negligible; however, pre-systemic conversion to beclometasone 17-monopropionate results in 41% of the dose being absorbed as the active metabolite.
Biološka uporabnost zaužitega beklometazondipropionata je zanemarljiva; vendar predsistemska pretvorba v beklometazon 17-monopropionat povzroči, da se 41 % odmerka absorbira kot aktivni presnovek.
Do not stop using Riarify or lower the dose, even if you are feeling better or you have no symptoms.
Pomembno je, da zdravilo Riarify uporabljate vsak dan. Ne prenehajte uporabljati zdravila Riarify in ne zmanjšujte odmerka, četudi se počutite bolje ali nimate simptomov.
Animal studies have shown impairment of fertility (see section 5.3).
Študije na živalih so pokazale vpliv na plodnost (glejte poglavje 5.3).
Dispensing date dd/mm/yyyy
dd/mm/llll
If mist appears after the inhalation, either from the inhaler or from the sides of the mouth, the procedure should be repeated from step 2.
Če se po inhalaciji pojavi meglica iz inhalatorja ali ustnih kotov, mora bolnik postopek ponoviti od 2.
Chemical and physical in-use stability has been demonstrated for 2 months at 25°C.
Kemična in fizikalna stabilnost med uporabo sta bili dokazani za 2 meseca pri temperaturi 25 °C.
A comparison across studies showed that the pharmacokinetics of beclometasone 17-monopropionate, formoterol and glycopyrronium is similar in COPD patients and in healthy subjects.
Primerjava med študijami je pokazala, da je farmakokinetika beklometazon 17-monopropionata, formoterola in glikopironija pri bolnikih s KOPB podobna kot pri zdravih prostovoljcih.
• fall in the level of some constituents of your blood: of certain white blood cells called granulocytes, of potassium or of cortisol
• upad ravni nekaterih sestavin krvi: nekaterih belih krvnih celic, imenovanih granulociti, kalija ali kortizola;
Hold your breath for as long as possible and, finally, remove the inhaler from your mouth and breathe out slowly.
Zadržite dih, kolikor dolgo ga lahko, nato pa vzemite inhalator iz ust in počasi izdihnite.
Glycopyrronium bromide is a high affinity muscarinic receptor antagonist with a greater than 4-fold selectivity for the human M3 receptors over the human M2 receptor as it has been demonstrated.
Glikopironijev bromid je antagonist muskarinskih receptorjev z visoko afiniteto in dokazali so, da je za humane receptorje M3 več kot 4-krat bolj selektiven kot za humane receptorje M2.
Cytochrome P450 isoenzymes CYP2D6, CYP2C19 and CYP2C9 are involved in the O-demethylation of formoterol.
V O-demetilacijo formoterola so vključeni izoencimi CYP2D6, CYP2C19 in CYP2C9 citokroma P450.
You and your doctor must make a decision whether to discontinue breast-feeding or to discontinue/abstain from Riarify therapy taking into account the benefit of breast-feeding for your child and the benefit of therapy for you.
Vi in zdravnik se morate odločiti med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Riarify, pri čemer morate pretehtati prednosti dojenja za otroka in prednosti zdravljenja za vas.
• if you have an overactive thyroid gland.
• če imate čezmerno aktivno žlezo ščitnico.
Check that the dose counter (60/120 puffs) has moved down by one or that the dose indicator (180 puffs) has rotated by a small amount.
Preverite, ali se je številka na števcu odmerkov (60/120 vdihov) zmanjšala za eno ali pa se je kazalnik odmerkov (180 vdihov) nekoliko obrnil.
Caution is also required when Riarify is used by patients with thyrotoxicosis, diabetes mellitus, pheochromocytoma and untreated hypokalaemia.
Previdnost je potrebna tudi pri uporabi zdravila Riarify pri bolnikih s tirotoksikozo, sladkorno boleznijo, feokromocitomom in nezdravljeno hipokaliemijo.
Glucocorticoids are excreted in human milk.
Glukokortikoidi se izločajo v materino mleko.
The cumulative urinary excretion of formoterol after single inhalation from a dry powder inhaler increased linearly in the 12-96 micrograms dose range.
Izločanje Kumulativno izločanje formoterola v urinu po enkratni inhalaciji iz inhalatorja s suhim praškom se je povečevalo linearno v razponu odmerka 12-96 mikrogramov.
In patients with severe hepatic impairment, Riarify should be used only if the expected benefit outweighs the potential risk (see section 5.2).
Pri bolnikih s hudo okvaro jeter se lahko zdravilo Riarify uporablja le, če so pričakovane koristi večje od možnih tveganj (glejte poglavje 5.2).
In COPD patients receiving repeated twice daily administration of inhaled glycopyrronium, the fraction of the dose excreted in urine ranged from 13.0% to 14.5% at steady state.
Pri bolnikih s KOPB, ki so prejeli ponavljajoče odmerke inhaliranega glikopironija dvakrat na dan, je bila frakcija odmerka, izločenega v urinu, v razponu od 13,0 % do 14,5 % v stanju dinamičnega ravnovesja.
• muscle cramps and pain in muscles
• mišični krči in bolečine v mišicah;
Take another puff, following the instructions starting again from step 2.
Naredite dodaten vdih: znova začnite pri 2. koraku in upoštevajte navodila.
Hypersensitivity reactions, including erythema, lips, face, eye and pharyngeal oedema
občasni preobčutljivostne reakcije, vključno z eritemom, ustnicami, obrazom, očmi in faringealnim edemom redki
Dermatitis allergic1
Bolezni imunskega sistema alergijski dermatitis1
Concomitant treatment with monoamine oxidase inhibitors, including medicinal products with similar properties such as furazolidone and procarbazine, may precipitate hypertensive reactions.
Sočasno zdravljenje z zaviralci monoaminooksidaze, vključno z zdravili, ki imajo podobne lastnosti kot furazolidon in prokarbazina, lahko pri bolnikih sproži hipertenzivno reakcijo.
Riarify contains beclometasone dipropionate, formoterol and glycopyrronium in a solution formulation resulting in an aerosol with extrafine particles with an average mass median aerodynamic diameter (MMAD) of around 1.1 micrometres and co-deposition of the three components.
Zdravilo Riarify vsebuje beklometazondipropionat, formoterol in glikopironij v obliki raztopine, iz katere nastane aerosol z izredno majhnimi delci s srednjim masnim aerodinamičnim premerom (MMAD - mass median aerodynamic diameter) približno 1,1 mikrometra in kodepozicijo treh učinkovin.
Their lips should then be placed around the mouthpiece, with the tongue flat under it.
Potem z ustnicami objemite ustnik, jezik naj bo plosko pod njim.
If any of the above applies to you, tell your doctor before you use Riarify.
Če karkoli od navedenega velja za vas, obvestite zdravnika, preden začnete uporabljati zdravilo
The fraction of an inhaled dose that is swallowed after administration with a metered dose inhaler may range between 60% and 90%.
Delež inhaliranega odmerka, ki ga bolnik pogoltne po uporabi zdravila z inhalatorjem z določenim odmerkom, je v razponu od 60 % do 90 %.
Not known (frequency cannot be estimated from the available data): • blurred vision.
Neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov):
Concomitant treatment with quinidine, disopyramide, procainamide, antihistamines, monoamine oxidase inhibitors, tricyclic antidepressants and phenothiazines can prolong the QT interval and increase the risk of ventricular arrhythmias.
Sočasno zdravljenje s kinidinom, dizopiramidom, prokainamidom, antihistaminiki, zaviralci monoaminooksidaze, tricikličnimi antidepresivi in fenotiazini lahko podaljša interval QT in poveča tveganje ventrikularnih aritmij.
Lower respiratory tract infection (fungal)
občasni okužbe spodnjih dihal (glivične)
Inhaled beclometasone dipropionate is rapidly absorbed through the lungs; prior to absorption there is extensive conversion to beclometasone 17-monopropionate via esterase enzymes that are found in most tissues.
Inhalirani beklometazondipropionat se hitro absorbira skozi pljuča; pred absorpcijo pride do ekstenzivne pretvorbe v beklometazon 17-monopropionat z encimi esteraze, ki so prisotni v večini tkiv.
• flu
• gripa;
Cleaning of the Riarify inhaler
Čiščenje inhalatorja z zdravilom Riarify
Do not remove the pressurised container from the inhaler and do not use water or other liquids to clean your inhaler.
Ne odstranite vsebnika pod tlakom iz inhalatorja, za čiščenje inhalatorja pa ne uporabljajte vode ali kakšne druge tekočine.
• upset stomach
• razdažen želodec;
The effect of organic cation transport inhibition (using cimetidine as a probe inhibitor of OCT2 and MATE1 transporters) in the kidneys on inhaled glycopyrronium disposition showed a limited increase in its total systemic exposure (AUC0-t) by 16% and a slight decrease in renal clearance by 20% due to co administration of cimetidine.
Učinek zaviranja organskega kationskega prenašalca (z uporabo cimetidina kot primarnega zaviralca prenašalcev OCT2 in MATE1) v ledvicah na dispozicijo inhaliranega glikopironija je pokazal omejeno povečanje skupne sistemske izpostavljenosti (AUC0-t) za 16 % in majhno zmanjšanje ledvičnega izločanja za 20 % zaradi sočasnega dajanja cimetidina.
After priming, the counter/indicator should read 60, 120 or 180.
Po pripravi mora števec/kazalnik odmerkov kazati 60, 120 ali 180.
Following intravenous dosing, the disposition of beclometasone dipropionate and its active metabolite is characterised by high plasma clearance (150 and 120 L/h respectively), with a small volume of distribution at steady state for beclometasone dipropionate (20 L) and larger tissue distribution for its active metabolite (424 L).
Po intravenskem odmerjanju je za dispozicijo beklometazondipropionata in njegovega aktivnega presnovka značilen velik očistek v plazmi (150 oz. 120 l/h), z majhno količino porazdelitve v stanju dinamičnega ravnovesja za beklometazondipropionat (20 l) in večjo porazdelitvijo njegovega aktivnega presnovka v tkivu (424 l).
Pack sizes of 1 container of 60, 120 or 180 actuations and multipacks of 2 or 3 containers of 120 actuations each.
Velikosti pakiranja so po 1 vsebnik s 60, 120 ali 180 sprožitev in skupna pakiranja z 2 ali 3 vsebniki s 120 sprožitev.
Psychomotor hyperactivity1, sleep disorders1, anxiety, depression1, aggression1, behavioural changes (predominantly in children) 1
občasni psihomotorična hiperaktivnost1, motnje spanja1, anksioznost, depresija1, agresija1, spremenjeno vedenje (predvsem pri otrocih)1
Additional instructions for specific groups of patients For patients with weak hands it may be easier to hold the inhaler with both hands.
Bolniki s šibkimi rokami bodo inhalator morda lažje držali z obema rokama.
Reduction of COPD exacerbations
Zmanjšanje poslabšanj KOPB
Following glycopyrronium inhalation, the lung bioavailability was 10.5% (with activated charcoal ingestion) while the absolute bioavailability was 12.8% (without activated charcoal ingestion) confirming the limited gastrointestinal absorption and indicating that more than 80% of glycopyrronium systemic exposure was from lung absorption.
Po inhalaciji glikopironija je bila biološka uporabnost v pljučih 10,5 % (z zaužitjem aktivnega oglja), medtem ko je bila absolutna biološka uporabnost 12,8 % (brez zaužitja aktivnega oglja), kar potrjuje omejeno absorpcijo v prebavilih in kaže, da je več kot 80 % sistemske izpostavljenosti glikopironiju posledica absorpcije v pljučih.
Single dose pharmacokinetic data (see section 5.2) have demonstrated that in comparison to routine use without a spacer device, the use of Riarify with the AeroChamber Plus spacer device increased the total systemic exposure (AUC0-t) to glycopyrronium.
Farmakokinetični podatki po enkratnem odmerku (glejte poglavje 5.2) so pokazali, da je v primerjavi z redno uporabo brez nastavka uporaba zdravila Riarify z nastavkom AeroChamber Plus povečala skupno sistemsko izpostavljenost (AUC0-t) glikopironiju.
Additional there are multipacks containing either 2 or 3 pressurised containers with 120 puffs, each.
Dodatno so na voljo skupna pakiranja, ki vsebujejo dva ali tri tlačne vsebnike, od katerih vsak omogoča 120 vdihov.
The elimination half-life determined after oral administration is 2-3 hours.
Razpolovni čas izločanja, ugotovljen po peroralnem dajanju, je 2 do 3 ure.
You should not use Riarify during breast-feeding.
Zdravila Riarify ne uporabljajte med dojenjem.
Glucocorticoids are widely used for the suppression of inflammation in chronic inflammatory diseases of the airways such as COPD.
Glukokortikoidi se obsežno uporabljajo za zaviranje vnetij pri kroničnih vnetnih boleznih dihalnih poti, kot je KOPB.
• medicines for treating heart disease (digoxin) can cause a fall in your blood potassium level.
• zdravili za zdravljenje srčnih bolezni (digoksin) lahko povzroči zmanjšanje koncentracije kalija v krvi.
Effect of renal impairment
Učinek okvare ledvic
Therefore, the index fingers should be placed on the top of the pressurised container and both thumbs on the base of the inhaler.
V ta namen je treba kazalca položiti na vrh, palca pa na spodnji del tlačnega vsebnika.
There are no or limited amount of data from the use of Riarify in pregnant women.
Podatkov o uporabi zdravila Riarify pri nosečnicah ni oziroma so omejeni.